1417 results about "Tumor tissue" patented technology

The invention relates to the technical field of medical image processing, in particular to a multimodal-based digestive tract tumor lesion image segmentation method and segmentation system. The method comprises the following steps: acquiring an alimentary canal tumor lesion image, and extracting an alimentary canal tumor ultrasonic image; evaluating the tumor invasion depth based on the digestive tract tumor ultrasonic image; performing focus three-dimensional visual modeling according to the tumor invasion depth to obtain a digestive tract tumor focus model; extracting a tumor tissue pathological image according to the digestive tract tumor lesion image; performing tumor region segmentation based on the tumor tissue pathological image to obtain digestive tract tumor region data; performing tissue arrangement anomaly detection based on the digestive tract tumor region data to obtain tissue arrangement anomaly data; and calculating a tissue arrangement disorder index according to the tissue arrangement abnormal data and the digestive tract tumor area data. According to the invention, the tumor identification accuracy and the malignant region segmentation precision are improved based on the medical image processing technology.

The invention relates to the technical field of medical image processing and tumor treatment, and provides a tumor image boundary identification method and system fused with a fluorescence boundary, and the method comprises the steps: collecting a tumor dynamic fluorescence image sequence and breathing waveform data through a fluorescence imaging device; performing multi-scale noise suppression processing on the image sequence to generate a preprocessed image without artifacts; extracting fluorescence intensity distribution characteristics through a multi-layer characteristic weighted fusion network and generating an intensity distribution matrix; constructing a motion compensation model according to the breathing waveform data, and correcting the boundary displacement of the intensity distribution matrix; fusing the corrected fluorescence features and the tumor tissue texture features to generate an initial tumor boundary contour; iterative topological optimization is carried out on the initial boundary, and boundary discontinuity is eliminated; and mapping the optimized boundary to a space coordinate system of the laser treatment equipment, generating a boundary mapping model and updating the boundary mapping model in real time. The precision and safety of laser treatment can be improved, and damage to normal tissue is reduced.

The invention discloses an intelligent processing method and system for multi-modal biological medicine data. The method comprises the following steps: acquiring a tumor tissue microscopic image and clinical characteristics of a diagnosed patient object; performing semantic coding on the clinical features to obtain clinical feature semantic understanding feature vectors; performing feature extraction on the tumor tissue microscopic image through a tumor tissue morphological feature extractor based on a deep neural network model to obtain a tumor tissue microscopic feature map; performing target significance analysis on the tumor tissue microscopic feature map to obtain a sequence of target manifestation tumor tissue microscopic local feature vectors; performing class attention interaction fusion processing on the sequence of the clinical feature semantic understanding feature vector and the target explicit tumor tissue microscopic local feature vector to obtain a multi-modal medical semantic fusion feature; and determining a tumor type label based on the multi-modal medical semantic fusion features. Therefore, the tumor type can be detected and judged, and powerful support is provided for the aspects of early diagnosis, personalized treatment and the like of tumors.

Electroporation-based therapies (EBTs) employ high voltage pulsed electric fields (PEFs) to permeabilize tumor tissue, resulting in changes in passive electrical properties detectable using electrical impedance spectroscopy (EIS). Currently, commercial potentiostats for EIS are limited by impedance spectrum acquisition time (˜10 s); this timeframe is much larger than pulse periods used with EBTs (˜1 s). Fourier Analysis SpecTroscopy (FAST) is introduced as a methodology for monitoring tissue inter-burst impedance (diagnostic FAST) and intra-burst impedance (therapeutic FAST) during EBTs. FAST is a rapid-capture (<<1 s) technique which enables monitoring of inter-burst and intra-burst impedance during EBTs in real-time. FAST identified a frequency which delineates thermal effects from electroporation effects in measured impedance. Significance: FAST demonstrates the potential to perform EIS, in addition to intra-burst impedance spectroscopy, using existing pulse generator topologies.

The invention provides a folate receptor targeting small molecule compound, a preparation method, a composition and application. Specifically provided is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof provided by the invention can be used as a small-molecule targeting fluorescence contrast agent for assisting surgical treatment, has the advantages of novel structure, good solubility, small steric hindrance and strong targeting property, can obviously improve the view field of tumor surgery, and is beneficial to efficiently and accurately implementing excision of pathological tissues such as tumor tissues, boundary tissues and the like. # imgabs0 #

The invention relates to the technical field of biological medicine, and discloses a pharmaceutical composition of paclitaxel dimer prodrug nanoparticles and a traditional Chinese medicine compound and application of the pharmaceutical composition, and the pharmaceutical composition is composed of Qiyuansanlong prescription freeze-dried powder and paclitaxel dimer prodrug nanoparticles; wherein the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) or GSH (glutathione) response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs), and the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) and GSH response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs). According to the pharmaceutical composition disclosed by the invention, a traditional Chinese and western medicine synergistic treatment system is innovatively constructed, and the advantage of multi-dimensional synergistic interaction is shown. Firstly, an NQO1 / GSH double-response type intelligent release system is adopted, and a biomarker highly expressed by tumor tissue can be specifically responded to realize precise drug release, so that the PTX concentration in tumors is improved compared with that of a traditional dosage form, and meanwhile, the drug circulation time is prolonged. Secondly, the active ingredients in the Qiyuansanlong prescription freeze-dried powder can significantly down-regulate the PD-L1 expression level, synergistically enhance CD4 + T and CD8 + T cell infiltration, and form chemical-immune dual killing effects.

An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same.Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided.The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.

A neurosurgery system for probing brain tissue of a patient for tumorous tissue. The system including a suction tool, an excitation source, an optical instrument, and a controller. The suction tool including a suction cannula defining a lumen, an optical fiber configured to transmit fluorescence emitted by the brain tissue; and an indicator configured to selectively emit visible light. An excitation source is configured to emit an excitation light having a wavelength to induce the fluorescence in the tumorous tissue. The optical instrument is coupled to the optical fiber. The optical instrument configured to convert the fluorescence emitted by the brain tissue and transmitted by the optical and configured to determine that the brain tissue is tumorous based on the electrical signal and activate the indicator based on the determination.

The present invention relates to magnetic, catalytically active, and radiosensitizing nanoparticles (NanoXcats) and the method for their production. A method is disclosed for the production of functionalized greigite nanoparticles with a narrowband size distribution (10-30 nm) for use in multimodal cancer therapy. NanoXcats are superparamagnetic Fe3S4 nanoparticles whose surfaces are equipped with polar functional groups. The surface structures of NanoXcats are suitable for conjugation with, or for covalent or electrostatic binding of, active substances, which may be cancer drugs, cell growth inhibitors, or NO donors. Due to the EPR effect, NanoXcats are preferentially internalized by tumor cells. The targeted accumulation of NanoXcats in tumor tissue is achieved by an external inhomogeneous magnetic field. NanoXcats exhibit enhanced catalytic activity in tumor cells.The catalytic activity of intracellular NanoXcats can be triggered, controlled, and enhanced by low-dose X-rays. Surface-bound drugs are additionally activated in tumor cells by the catalytic activity of NanoXcats. NanoXcats act as superoxide dismutase, nitric oxide synthase, and Fenton catalyst. They catalyze, for example, reactions of the superoxide anion radical to hydrogen peroxide, of L-arginine to NO, and of hydrogen peroxide to the hydroxyl radical.

The invention discloses a molecular probe for in-vivo copper ion detection and a preparation method and application thereof, the chemical structural formula of the molecular probe is as follows: # imgabs0 #, the molecular probe provided by the invention can specifically respond to copper ions in a tumor subacid environment so as to cause change of an absorption spectrum, and a photoacoustic signal is started so as to detect the copper ions in the tumor subacid environment. Normal tissues and tumor tissues can be accurately distinguished, and accurate detection of the copper ions in the living tumor is realized.

The invention relates to an immune humanized liver cancer patient-sourced xenotransplantation mouse model and a construction method and application thereof, and belongs to the technical field of medical research and biologication.The immune humanized liver cancer PDX model is innovatively constructed by optimizing transplantation of tumor tissues and introducing and screening immune cells, and the model has the advantages of being high in specificity, high in sensitivity and high in reliability. The defects of a traditional PDX model in immune system and immunotherapy evaluation are overcome. The model has tumor characteristics of liver cancer patients and a functional human immune system, has reliable immune response and anti-cancer treatment evaluation capability, and provides scientific and reliable model support for research and screening of novel liver cancer immunotherapy.

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.

The invention relates to Chinese pulsatilla root and stem exosome-like vesicles as well as a preparation method and application thereof. The preparation method comprises the following steps: juicing Chinese pulsatilla roots, filtering, and collecting filtrate; and centrifuging the filtrate, collecting the precipitate, re-suspending, and filtering to obtain a solution containing the exosome-like vesicles of the Chinese pulsatilla roots. Compared with the prior art, the Chinese pulsatilla root and stem exosome-like vesicles extracted by the method can inhibit malignant progression, including proliferation and migration, of lung cancer, and cell uptake and animal living imaging prove that the Chinese pulsatilla root and stem exosome-like vesicles can be taken by cells and can be enriched in tumor tissues at the same time.

The application provides a novel DNA methylation marker TAGMe-3 for tumor identification and use thereof. The TAGMe-3 gene sequence region has significant methylation difference between cancer tissues and paracancer tissues. As long as abnormal high methylation state of the TAGMe-3 gene sequence region is detected, the subject is determined to belong to a tumor high-risk population. Moreover, the significant difference of the TAGMe-3 presented between tumor tissues and non-tumor tissues exists in different types of tumors (Pan-cancer) in a wide range.

The invention relates to a computer-implemented method for assessing a risk of breast cancer recurrence, to a computer program having instructions which when executed by a computing device or system cause the computer device or system to perform the method as well as to a data-processing system comprising means for carrying out the method for assessing a risk of breast cancer recurrence. The method of the invention is for example performed by whole slide image (WSI) processing, wherein the risk of breast cancer recurrence is assessed from a WSI of a tumor tissue.

The utility model provides a pathological section sampling device, which belongs to the technical field of section sampling and comprises a slicing machine, a first conveying belt, a guide roller, a second conveying belt, a slide, a receiving mechanism and a cutting mechanism. A slicing machine is used for slicing the wax-coated tumor tissue, because a wax block needs to be cut into continuous long pieces, the wax block needs to be cut alternately up and down, a receiving mechanism is used for driving a guide roller to move up and down, then the slices are received, and the situation that the slices are far away from a first conveying belt, and consequently the slices are broken is avoided; then, after the slices reach the specified length, the slices are cut off through the cutting mechanism, move forwards through the first conveying belt and finally fall onto the slides on the second conveying belt, when the slices completely fall onto the slides, the second conveying belt moves, and then another slide is moved to the position of the first conveying belt; further, pathological sections can be sampled, manual sample picking is not needed, and contact between medical staff and the sections is reduced.

The invention discloses an engineered autologous tumor tissue scaffold and application thereof, and the engineered autologous tumor tissue scaffold is prepared by performing specific treatment on autologous tumor tissue to induce immunogenic cell death of the tumor tissue, and then sequentially performing freezing and drying steps; the engineered autologous tumor tissue scaffold can be used for loading dendritic cells and constructing personalized tumor vaccines. According to the stent, autologous tumor tissue is adopted, so that a specific and comprehensive tumor antigen pedigree is reserved, and multi-epitope immunostimulation is provided; and meanwhile, excellent biocompatibility is ensured, the immunological rejection risk is reduced, and relatively high safety is ensured.

The invention discloses organic nano composite hydrogel as well as a preparation method and application of the organic nano composite hydrogel, and belongs to the technical field of biological medicine delivery. The polysaccharide-based nano prodrug in the composite hydrogel can be subjected to surface protonation under the stimulation of a tumor extracellular slightly acidic environment, so that cellular uptake is promoted, low-pH / high-concentration glutathione in tumor cells is responded, intracellular aggregation and controllable release of the nano drug are realized, the retention time of the drug in the cells is prolonged, and the bioavailability of the drug is improved. The technical effect of killing tumor cells through combined chemotherapy is achieved. According to the preparation method disclosed by the invention, the release of the polysaccharide-based nano prodrug from the hydrogel and the tissue infiltration capacity are accelerated by adopting fluorinated orthoester, the infiltration of the polysaccharide-based nano prodrug to cells is increased, and then the drug-loaded compound is encapsulated by using gellan gum, so that the slow-release effect of the polysaccharide-based nano prodrug is enhanced; therefore, the efficient enrichment of the medicine at the tumor part is realized.

The invention provides a tumor living body sampling device, and relates to the field of biological sampling, the tumor living body sampling device comprises: a sampler main body, the sampler main body is a pistol-shaped structure; the inner sampling needle is coaxially and rotatably connected to the inner side of the reversing seat, the inner sampling needle is rotatably connected to the inner side of the sampling outer cylinder, the right cross sections of the sampling outer cylinder and the inner sampling needle are of arch-shaped structures, and the right end parts of the sampling outer cylinder and the inner sampling needle are of needle-shaped spine structures; hollow sampling openings are formed in arch-shaped parts on the right sides of the sampling outer cylinder and the inner sampling needle; the sampling transmission assembly is arranged in the sampler main body, and the sampling operation block drives the sampling outer cylinder and the inner sampling needle to rotate reversely at the same time through the sampling transmission assembly. The tumor tissue is rapidly and completely cut off, tearing damage is avoided, samples are isolated from the tissue, the samples are prevented from being mixed, and the problems that in the existing sampling process, the tissue is difficult to effectively cut off, tissue tearing is easily caused, and tissue samples are not pure are solved.

The invention relates to the technical field of medical image processing, and discloses a neurovascular tumor recognition method and system based on multi-modal image fusion, and the system comprises a multi-dimensional collection module and an intelligent recognition module. According to the neural vascular tumor identification method and system based on multi-modal image fusion, PET / CT images and MRI images of a tumor part are obtained through a multi-dimensional acquisition module and are classified to form an image set, and an intelligent identification module carries out gray scale range standardization processing on the images of different modalities according to the same time point; according to the method, the difference between images collected by different devices or time points is eliminated, the images are registered and aligned to a unified three-dimensional coordinate system, the visual fusion registration capacity is high, and an intelligent recognition module analyzes the horizontal diameter and the vertical diameter of tumor tissue and the growth state of the tumor tissue according to the three-dimensional coordinate system, generates a tumor data set and a compression index and displays the tumor data set and the compression index. The compression degree of the tumor tissue on the blood vessel wall is evaluated, corresponding treatment suggestions are output, and the intelligent recognition and diagnosis effect is good.

The invention provides a dual-targeting carrier material, a preparation method thereof and a preparation method of oleanolic acid nanoparticles wrapped by the dual-targeting carrier material, and belongs to the technical field of medicines. The oleanolic acid targeting nanoparticles are prepared by taking a dual-targeting high-molecular copolymer as a carrier material and adopting an emulsification-solvent evaporation method, so that the oleanolic acid can be protected from being quickly degraded, and the in-vivo circulation time of the oleanolic acid can be prolonged. Meanwhile, targeted delivery of oleanolic acid is realized through a targeted group, the concentration of the drug in tumor tissues is improved, and toxic and side effects on normal tissues are reduced. An MTT method is adopted, the inhibition effect of the oleanolic acid nanoparticles on cell growth is researched, and the result shows that the oleanolic acid targeting nanoparticles have a stronger effect of inhibiting tumor cell proliferation compared with an oleanolic acid raw material medicine.

The present invention belongs to the technical field of medical devices, and provides an ablation device with a cutting function, including an insulating sleeve with a through first channel; an ablation electrode with a hollow structure, which is arranged at one end of the insulating sleeve, and the ablation electrode has a plurality of ablation claws, and the ablation claws can expand toward the outside direction of the ablation electrode under stress, wherein one or more ablation claws on the ablation electrode are provided with a cutting edge for cutting; and a puncture needle with a needle tip, which is arranged at the second end of the ablation electrode; by applying an external force to the ablation electrode to expand the ablation electrode, the ablation claws of the ablation electrode are transformed and maintained from an initial state without stress to an expanded state after stress. The present application arranges a plurality of ablation claws that can expand under stress, combined with the cutting edges arranged on the ablation claws, thereby achieving the separation and expansion of tumor tissue, avoiding the occurrence of an ablation vacuum zone, and allowing the tumor tissue to be completely ablated.

The invention discloses a cathepsin B activated fluorescent probe which comprises a dicyanoisosulfone fluorescent report unit and a cathepsin B specific restriction enzyme cutting site GFLG peptide chain. When CTSB specifically cuts a GFLG peptide chain, a DCO molecule with an amino group with relatively strong electron donating ability is generated, so that the fluorescence emission behavior of the probe is rapidly activated through a one-step enzyme catalysis reaction. The invention also provides a preparation method of the cathepsin B activated fluorescent probe. The invention also provides a nano particle for packaging the cathepsin B activated fluorescent probe, and the nano particle is simple in preparation process and mild in reaction condition. The cathepsin B activated fluorescent probe is prepared into nanoparticles, and the nanoparticles can realize accumulation of the material in tumor tissues and accurate imaging in apoptotic tumor cells by enhancing the permeation retention effect, have better biocompatibility and can be used for detecting the apoptotic tumor cells.

The invention provides application of TRMT61A and its inhibitor tetramethylthiuram disulfide in tumor immunotherapy, and relates to the technical field of biological medicine, clinical research proves that RNA m1A methyltransferase TRMT61A is highly expressed in tumor tissues and is related to poor prognosis of tumor patients, and can be used as one of tumor therapy targets. Meanwhile, high expression of the TRMT61A is related to poor prognosis of a tumor patient receiving anti-PD-1 immunotherapy, and after anti-PD-1 antibody immunotherapy is carried out on the patient with low TRMT61A expression level in the tumor of the patient, pathological complete relief is easier. Tetramethylthiuram disulfide inhibits TRMT61A, inhibits m1A modification regulation of TRMT61A on PD-L1 mRNA, increases PD-L1 protein expression, and is combined with a PD-1 antibody drug to significantly enhance the immunotherapy effect of the anti-PD-1 immune checkpoint drug in treating malignant tumors.

The invention belongs to the technical field of biomedicine, and particularly relates to tumor neoantigen polypeptide based on EGFR gene mutation and application of the tumor neoantigen polypeptide. According to the effective method for predicting and screening the tumor neoantigen by using the tumor neoantigen prediction platform, the specific mutation of tumor tissues is obtained, and the neoantigen polypeptide with high immunogenicity, high affinity and high activation effect is more accurately predicted; the screened new antigen polypeptide makes up the blank of individualized antigen peptide in treatment of lung cancer NSCLC patients with EGFR-L858R somatic mutation, can be synthesized in a large scale, is used for subsequent standardized and individualized immunotherapy of EGFR-L858R mutation tumor patients, and has a good clinical application prospect.

The invention provides an aza-BODIPY molecule with NIR-II fluorescence emission and I-type photodynamic activity and a preparation method thereof. The aza-BODIPY molecule has good light absorption in a near-infrared (NIR) region, the emission peak of the aza-BODIPY molecule is prolonged to a near-infrared second region (NIR-II), and the aza-BODIPY molecule shows an ultrahigh NIR-II fluorescence quantum yield of 13%. Meanwhile, the photosensitizer prepared by adopting aza-BODIPY molecules can effectively generate I-type active oxygen species, namely superoxide anion free radicals, under the excitation of 808nm laser. On the basis, high-resolution tumor fluorescence imaging can be realized by utilizing NIR-II fluorescence of the aza-fluorine boron fluorescent sensitizer, and the aza-fluorine boron fluorescent sensitizer is used for accurate and efficient NIR-II fluorescence imaging mediated I-type photodynamic therapy of deep tumor tissues.

The invention relates to the technical field of biopsy puncture, and discloses a tumor biopsy puncture device for biopsy sampling, the tumor biopsy puncture device comprises an outer needle assembly and an inner needle assembly, the outer needle assembly comprises a needle base and an outer needle tube fixed with the needle base, the inner needle assembly comprises a needle cylinder and an inner needle core slidably arranged in the needle cylinder, a needle cavity is arranged at the needle tip end of the inner needle core, and the needle cavity is communicated with the needle base. An ejection mechanism is arranged in the needle cylinder, the ejection mechanism is used for triggering the inner needle core to eject outwards in the length direction of the outer needle tube, and the ejection mechanism comprises a connecting part fixed to the inner needle core, a locking piece arranged on the connecting part and used for limiting the position of the inner needle core and a pull rod fixed to the connecting part and capable of penetrating out of the needle cylinder in a sliding mode. According to the tumor biopsy puncture equipment for biopsy sampling, by arranging the ejection mechanism, compared with an existing manual operation mode, the ejection force of the inner needle core is adjusted by changing the stretching or compression degree of the elastic component, and the cutting requirements of tumor tissues of different textures can be met.

A computer apparatus and method for identifying and visualizing tumors in a histological image and measuring a tumor margin are provided. A CNN is used to classify pixels in the image according to whether they are determined to relate to nontumorous tissue, or one or more classes for tumorous tissue. Segmentation is carried out based on the CNN results to generate a mask that marks areas occupied by individual tumors. Summary statistics for each tumor are computed and supplied to a filter which edits the segmentation mask by filtering out tumors deemed to be insignificant. Optionally, the tumors that pass the filter may be ranked according to the summary statistics, for example in order of clinical relevance or by a sensible order of review for a pathologist. A visualization application can then display the histological image having regard to the segmentation mask, summary statistics and / or ranking. Tumor masses extracted by resection are painted with an ink to highlight its surface region. The CNN is trained to distinguish ink and no-ink tissue as well as tumor and no-tumor tissue. The CNN is applied to the histological image to generate an output image whose pixels are assigned to the tissue classes. Tumor margin status of the tissue section is determined by the presence or absence of tumor-and-ink classified pixels. Tumor margin involvement and tumor margin distance are determined by computing additional parameters based on classification-specified inter-pixel distance parameters.

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The invention discloses a Claudin18.2-targeting nano antibody and application thereof, and belongs to the technical field of molecular biology. Aiming at the unique advantages of a nano antibody in the prior art, the invention provides a nano antibody targeting Claudin18.2, the amino acid sequence of the targeting nano antibody is shown as SEQ ID NO.1, and the nano antibody has relatively strong affinity with Claudin18.2 positive cells 293T-Claudin18.2, and can be combined with Claudin18.2 protein expressed on the surfaces of the cells. The targeted Claudin18.2 nano antibody provided by the invention can be prepared through in-vitro engineering bacterium mass expression, can be applied to preparation of protein detection antibodies or therapeutic antibodies, can be used for in-vivo and in-vitro detection of tumor tissues expressed by Claudin18.2, and has important commercial value in clinical disease diagnosis and treatment.